Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sarepta Therapeutics Inc    SRPT

SAREPTA THERAPEUTICS INC (SRPT)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2019 01/15/2019 01/16/2019 01/17/2019 01/18/2019 Date
118.6(c) 118.73(c) 119.26(c) 121.32(c) 122.8(c) Last
774 372 922 657 651 694 841 444 583 602 Volume
-1.63% +0.11% +0.45% +1.73% +1.22% Change
More quotes
Financials (USD)
Sales 2018 301 M
EBIT 2018 -268 M
Net income 2018 -275 M
Finance 2018 405 M
Yield 2018 -
Sales 2019 417 M
EBIT 2019 -198 M
Net income 2019 -198 M
Finance 2019 458 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 25,9x
EV / Sales2019 18,6x
Capitalization 8 206 M
More Financials
Company
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to... 
More about the company
Surperformance© ratings of Sarepta Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on SAREPTA THERAPEUTICS INC
01/07SAREPTA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regu..
AQ
01/05SAREPTA THERAPEUTICS : inks deal to bolster gene therapy manufacturing
AQ
01/03SAREPTA THERAPEUTICS : Enters into Long-term Strategic Relationship with Aldevro..
AQ
01/02SAREPTA THERAPEUTICS : Enters into Long-term Strategic Relationship with Aldevro..
AQ
01/02SAREPTA THERAPEUTICS : to Present at the 37th Annual J.P. Morgan Healthcare Conf..
AQ
2018Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 56..
GL
2018SAREPTA THERAPEUTICS : Completes Submission of New Drug Application Seeking Appr..
AQ
2018SAREPTA THERAPEUTICS : Completes Submission of New Drug Application Seeking Appr..
AQ
2018SAREPTA THERAPEUTICS, INC. : Other Events (form 8-K)
AQ
2018Sarepta Therapeutics Completes Submission of New Drug Application Seeking App..
GL
More news
Analyst Recommendations on SAREPTA THERAPEUTICS INC
More recommendations
Sector news : Bio Therapeutic Drugs
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/08NEKTAR THERAPEUTICS : Shares Up Tuesday as Gilead Collaboration Announced -- Mar..
DJ
01/08GlaxoSmithKline to look for early-stage assets - CEO
RE
01/08Lilly's Deal Boosts Its Cancer Arsenal -- WSJ
DJ
01/07Eli Lilly to Buy Loxo Oncology in $8 Billion Deal -- 5th Update
DJ
More sector news : Bio Therapeutic Drugs
Chart SAREPTA THERAPEUTICS INC
Duration : Period :
Sarepta Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAREPTA THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsNeutralBearishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 194 $
Spread / Average Target 58%
EPS Revisions
Managers
NameTitle
Douglas S. Ingram President, Chief Executive Officer & Director
M. Kathleen Behrens Chairman
Sandesh Mahatme Executive VP, Chief Financial & Business Officer
Guriqbal S. Basi Chief Scientific Officer
Gilmore O’Neill Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
SAREPTA THERAPEUTICS INC12.53%8 206
GILEAD SCIENCES10.60%89 493
VERTEX PHARMACEUTICALS14.97%49 757
REGENERON PHARMACEUTICALS11.75%44 532
GENMAB-4.59%9 536
NEUROCRINE BIOSCIENCES, INC.28.18%8 300